drug
lebrikizumab
Marketedupdated 3mo agoby Lilly USA LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for atopic eczema and eczematoid dermatitis and 5 investigational indications.
all catalysts(3)
Trials studying lebrikizumab
- phase1A Study of LAD106 in Healthy Adult Participants
- phase3Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
- phase3A Study of Lebrikizumab in Adults With Nummular Eczema
- phase3A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
- phase4A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
- phase3A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
- phase3A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
- phase3A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
News(1)
- Chasing Dupixent, a biotech aims to make better antibody drugs for eczemaInfinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.biopharma_dive · 3d ago
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that